The earnings before interest, tax, depreciation and ammortisation (EBITDA) rose 40.7% YoY to Rs 199 crore. The EBITDA margins expanded 250 basis points YoY to 25.1%. Average occupied bed days increased by 16.2% y-o-y, representing an occupancy of 58.1% in Q1 FY24 on increased bed capacity.
Average revenue per occupied bed (ARPOB) grew by 7.1% y-o-y to Rs 63,148; In-patient volume increased by 19.4% and out-patient volume increased by 17.5% y-o-y.
Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 23.4% in Q1 FY23 to 28.9% in Q1 FY24 amounting to Rs. 230 crore.
Revenue from international patients increased by 45% y-o-y to Rs. 48 crore driven by increased volume and realization.
In-house out-patient pharmacy business increased by 43% y-o-y to Rs. 26.6 crore in Q1 FY24.
“The company continues to deliver strong year-on-year and sequential growth driven by higher patient volumes and improvement in realization,” said Pankaj Sahni, Group CEO and director.
